We are live on ! Find out more

Addex Therapeutics

ADXN

Market cap $5.42M

3.09 USD

+0.16

5.46%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

3.07

-0.02

0.65%

1 day

5.46%

5 days

5.82%

1 month

11.96%

3 months

-44.82%

6 months

-55.6%

Year to date

-61.8%

1 year

-66.59%

5 years

-98.04%

10 years

-98.93%

About: Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

Employees: 3

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that 93,000,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary.

ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-253 and plans to advance NTX-253 into Phase 2 clinical development.

Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Addex Therapeutics Announces Executive Management Changes

Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development and member of the Executive Management.

Addex Therapeutics Announces Executive Management Changes

Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript

Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript

Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”).

Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior

Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on September 28, 2026.

Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Market (ATM) offering agreement with H.C.

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript

Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript

Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update.

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

See News Rankings

Price charts implemented using Lightweight Charts™